You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed and Resistant Classical Hodgkin's Disease

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    The Federal Budget-Funded Institution National Medical Surgical
Oct 31, 2022

Hodgkin Lymphoma Trial in Salt Lake City (Axatilimab, Nivolumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Salt Lake City, Utah
    Huntsman Cancer Institute at the University of Utah
Feb 1, 2023

Classical Hodgkin Lymphoma Trial in Philadelphia (Itacitinib, Everolimus)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Nov 28, 2022

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • GEN3017
  • (no location specified)
Aug 25, 2023

Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • brentuximab vedotin
  • (no location specified)
Aug 18, 2022

Classical Hodgkin Lymphoma Trial in Cologne (Pembrolizumab plus Chemotherapy (ICE or DHAP))

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Pembrolizumab plus Chemotherapy (ICE or DHAP)
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Aug 5, 2022

Hodgkin Lymphoma Trial in Saint Petersburg (Prolgolimab, Combination with prolgolimab and bendamustine)

Recruiting
  • Hodgkin Lymphoma
  • Saint Petersburg, Russian Federation
  • +1 more
Mar 3, 2023

Hodgkin Lymphoma Trial in Beijing (Chidamide, Camrelizumab, Decitabine)

Recruiting
  • Hodgkin Lymphoma
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
Aug 12, 2020

Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

Terminated
  • Hodgkin's Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 22, 2022

Hodgkin Lymphoma Trial (favezelimab/pembrolizumab, bendamustine, gemcitabine)

Not yet recruiting
  • Hodgkin Lymphoma
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Aug 18, 2022

Intensive Monitoring Study on Tyvyt

Recruiting
  • Relapsed or Refractory Classical Hodgkin's Lymphoma
    • Beijing, China
      Peking Union Medical College Hospital
    Sep 14, 2022

    Hodgkin Lymphoma Trial (pembrolizumab)

    Active, not recruiting
    • Hodgkin Lymphoma
    • pembrolizumab
    • (no location specified)
    May 30, 2022

    Hodgkin Lymphoma Trial in Cologne (Pembrolizumab)

    Not yet recruiting
    • Hodgkin Lymphoma
    • Cologne, Germany
      1st Department of Medicine, Cologne University Hospital
    Sep 19, 2023

    Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma Trial in Guangzhou (PD-1 inhibitor, PD-1

    Recruiting
    • Classical Hodgkin Lymphoma
    • Refractory or Relapsed Classical Hodgkin Lymphoma
    • PD-1 inhibitor
    • PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
    • Guangzhou, Guangdong, China
    • +2 more
    May 6, 2022

    Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

    Recruiting
    • Relapsed Hodgkin Lymphoma
    • Refractory Hodgkin Lymphoma
    • Nivolumab
    • Pembrolizumab
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Jul 22, 2022

    Recurrent/Refractory Classical Hodgkin's Lymphoma Trial in Tianjin (AK105,Anrotinib HCl)

    Enrolling by invitation
    • Recurrent/Refractory Classical Hodgkin's Lymphoma
    • AK105，Anrotinib hydrochloride
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Insititute & Hospital
    Jan 12, 2023

    Hodgkin Lymphoma Trial (Gemcitabine, Dexamethasone, Cisplatin)

    Not yet recruiting
    • Hodgkin Lymphoma
    • (no location specified)
    May 9, 2022

    Relapsed/Refractory Classical Hodgkin Lymphoma Trial in Goyang (Brentuximab vedotin)

    Recruiting
    • Relapsed/Refractory Classical Hodgkin Lymphoma
    • Brentuximab vedotin
    • Goyang, Gyeonggi-do, Korea, Republic of
      Hyeon-Seok Eom
    Feb 12, 2022

    Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma Trial in Seoul

    Completed
    • Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma
      • Seoul, Gangnam-Gu, Korea, Republic of
        Samsung Medical Center
      Feb 4, 2022

      Hodgkin Disease Lymphoma Trial in China (Penpulimab, Investigator's choice of Chemotherapy)

      Recruiting
      • Hodgkin Disease Lymphoma
      • Guangzhou, Guangdong, China
      • +5 more
      Feb 15, 2022

      Advanced Classical Hodgkin's Lymphoma in Brazil Treated With

      Not yet recruiting
      • Hodgkin Lymphoma
      • No Intervention
      • Salvador, Bahia, Brazil
      • +5 more
      Oct 23, 2023

      Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent Trial in United States (Nivolumab, Autologous

      Recruiting
      • Classical Hodgkin Lymphoma
      • +2 more
      • Duarte, California
      • +4 more
      Jun 27, 2022

      Hodgkin Lymphoma Trial in United States (Ruxolitinib, Nivolumab)

      Recruiting
      • Hodgkin Lymphoma
      • Chicago, Illinois
      • +4 more
      Feb 16, 2022

      Classical Hodgkin Lymphoma Trial in China (Tislelizumab, Salvage Chemotherapy)

      Recruiting
      • Classical Hodgkin Lymphoma
      • Beijing, Beijing, China
      • +6 more
      Jan 4, 2022